<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00513266</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000559146</org_study_id>
    <secondary_id>CHUV-CH-OCFL-BC</secondary_id>
    <secondary_id>EU-20741</secondary_id>
    <nct_id>NCT00513266</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer With Liver Metastases or Lung Metastases That Are Potentially Removable by Surgery</brief_title>
  <official_title>Oxaliplatin-CPT-11-5-FU-Leucovarin + Bevacizumab and Cetuximab (OCFL-BC) as a Combination Regimen for Systemic Treatment of Advanced Colorectal Carcinoma With Potentially Resectable Liver and/or Lung Metastases. A Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Vaudois</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, irinotecan, fluorouracil and&#xD;
      leucovorin, work in different ways to stop the growth of tumor cells, either by killing the&#xD;
      cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab and&#xD;
      cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to&#xD;
      grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances&#xD;
      to them. Giving combination chemotherapy together with monoclonal antibody therapy may kill&#xD;
      more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving combination chemotherapy together&#xD;
      with monoclonal antibody therapy works in treating patients with advanced colorectal cancer&#xD;
      with liver metastases or lung metastases that are potentially removable by surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To determine the pathological complete response (CR) rate in resected patients assessed&#xD;
           on lesions of less than or equal to 30 mm in size.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To determine the clinical CR rate in all patients.&#xD;
&#xD;
        -  To determine toxicity and tolerability of this regimen (pre- and postoperative&#xD;
           toxicity).&#xD;
&#xD;
        -  To evaluate perioperative safety in these patients.&#xD;
&#xD;
        -  To determine disease-free survival (time to progression in unresected patients) and&#xD;
           overall survival of the whole study population.&#xD;
&#xD;
        -  To determine resectability in these patients.&#xD;
&#xD;
        -  To evaluate markers that predict the occurrence of a pathological CR or a non-response&#xD;
           in pathological material (resected liver metastasis) and biological material collected&#xD;
           from these patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive cetuximab IV over 1-2 hours on days 1, 8, 15, 22, and 29, oxaliplatin IV&#xD;
      over 2 hours on days 1 and 15, irinotecan hydrochloride IV over 30 minutes on days 8 and 22,&#xD;
      fluorouracil IV over 24 hours on days 1, 8, 15, and 22, leucovorin calcium IV on days 1, 8,&#xD;
      15, and 22, and bevacizumab IV over 30-90 minutes on days 1 and 15. Treatment repeats every 5&#xD;
      weeks for up to 3 courses in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients who are able to undergo liver resection receive bevacizumab on day 1 only of course&#xD;
      3 and undergo liver resection 3 weeks after chemotherapy. Beginning 4 weeks after liver&#xD;
      resection, patients receive 2 additional courses of chemotherapy as adjuvant therapy.&#xD;
&#xD;
      Patients undergo tumor tissue and blood sample collection periodically for biological&#xD;
      studies. Samples are analyzed for markers that predict the occurrence of a complete&#xD;
      pathological response (pCR) or a non-response.&#xD;
&#xD;
      After completion of study treatment, patients are followed every 3 months for the first 2&#xD;
      years and then every 6 months thereafter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>June 2007</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathological complete response rate of lesions of less than or equal to 30 mm in size assessed by pathologic examination in resected specimens</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response as assessed by NCIC criteria</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity as assessed by NCIC criteria</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Metastatic Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>cetuximab</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>irinotecan hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leucovorin calcium</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxaliplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>biopsy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>neoadjuvant therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          -  Histologically confirmed metastatic colorectal adenocarcinoma&#xD;
&#xD;
          -  Bidimensionally measurable metastatic disease limited to the liver and considered&#xD;
             curatively resectable after response to systemic therapy as assessed by a surgical&#xD;
             board&#xD;
&#xD;
               -  Additional metastatic disease to the lungs consisting of no more than 3&#xD;
                  potentially resectable lesions allowed&#xD;
&#xD;
               -  Must have at least one lesion of 30 mm or less&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  History or evidence upon physical examination of CNS disease unless adequately treated&#xD;
             (e.g., uncontrolled seizure with standard medical therapy or history of stroke)&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          -  Performance status ≤ 1&#xD;
&#xD;
          -  Life expectancy &gt; 12 weeks&#xD;
&#xD;
          -  WBC ≥ 3,000/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Creatinine 1.25 x upper limit of normal (ULN)&#xD;
&#xD;
          -  Bilirubin 1.25 x ULN (1.5 x ULN if liver metastasis)&#xD;
&#xD;
          -  AST and ALT ≤ 3 x ULN (≤ 5 x ULN if liver metastasis)&#xD;
&#xD;
          -  Woman and men of childbearing age must use adequate contraception&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Pregnancy (positive serum pregnancy test) or lactation&#xD;
&#xD;
          -  Chronic diarrhea ≥ grade 2&#xD;
&#xD;
          -  Other serious illness or medical condition including any of the following:&#xD;
&#xD;
               -  Unstable cardiac disease requiring treatment&#xD;
&#xD;
               -  Congestive heart failure or angina pectoris even if medically controlled&#xD;
&#xD;
               -  Significant arrhythmias&#xD;
&#xD;
               -  History of significant neurologic or psychiatric disorders including psychotic&#xD;
                  disorders, dementia, or seizures that would prohibit the understanding and giving&#xD;
                  of informed consent&#xD;
&#xD;
               -  Active uncontrolled infection&#xD;
&#xD;
               -  Severe hypercalcemia&#xD;
&#xD;
               -  Other serious underlying medical condition that could impair the ability of the&#xD;
                  patient to participate in the study&#xD;
&#xD;
               -  Neuropathy &gt; grade 1 of any etiology&#xD;
&#xD;
          -  Known DPD deficiency&#xD;
&#xD;
          -  Known severe polyneuropathy&#xD;
&#xD;
          -  Known allergy to Chinese hamster ovary cell proteins, other recombinant human or&#xD;
             humanized antibodies, any excipients of bevacizumab formulation, or any other study&#xD;
             drugs&#xD;
&#xD;
          -  Chronic inflammatory bowel disease&#xD;
&#xD;
          -  Acute or subacute intestinal occlusion&#xD;
&#xD;
          -  History of previous arterial thromboembolism&#xD;
&#xD;
          -  Uncontrolled hypertension&#xD;
&#xD;
          -  Evidence of bleeding diathesis or coagulopathy&#xD;
&#xD;
          -  Serious nonhealing wound, ulcer, or bone fracture&#xD;
&#xD;
          -  History of tumor other than basocellular carcinoma of the skin&#xD;
&#xD;
          -  Peripheral neuropathy &gt; grade 1 of any origin (e.g., alcohol)&#xD;
&#xD;
          -  Significant traumatic injury within 28 days prior to study treatment&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  No prior chemotherapy for metastatic disease&#xD;
&#xD;
               -  Prior adjuvant chemotherapy permitted if interval since last treatment&#xD;
                  administration and recurrence is &gt; 6 months&#xD;
&#xD;
          -  Major surgical procedure or open biopsy within 28 days prior to study treatment or&#xD;
             anticipation of the need for major surgical procedure during the course of the study&#xD;
&#xD;
          -  Treatment in a clinical trial within 30 days prior to study entry&#xD;
&#xD;
          -  Concurrent treatment with other experimental drugs or other anticancer therapy&#xD;
&#xD;
          -  Current or recent use (within 10 days prior to study treatment) of full-dose oral or&#xD;
             parenteral anticoagulants for therapeutic purposes&#xD;
&#xD;
          -  Chronic daily treatment with aspirin (&gt; 325 mg/day)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arnaud Roth, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hopital Cantonal Universitaire de Geneve</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kantonspital Aarau</name>
      <address>
        <city>Chur</city>
        <zip>CH-7000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Cantonal Universitaire de Geneve</name>
      <address>
        <city>Geneva</city>
        <zip>CH-1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois</name>
      <address>
        <city>Lausanne</city>
        <zip>CH-1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Regional de Sion-Herens-Conthey</name>
      <address>
        <city>Sion</city>
        <zip>CH -1951</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>June 2009</verification_date>
  <study_first_submitted>August 6, 2007</study_first_submitted>
  <study_first_submitted_qc>August 6, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2007</study_first_posted>
  <last_update_submitted>August 6, 2009</last_update_submitted>
  <last_update_submitted_qc>August 6, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 7, 2009</last_update_posted>
  <keyword>recurrent rectal cancer</keyword>
  <keyword>stage IV rectal cancer</keyword>
  <keyword>recurrent colon cancer</keyword>
  <keyword>stage IV colon cancer</keyword>
  <keyword>adenocarcinoma of the colon</keyword>
  <keyword>adenocarcinoma of the rectum</keyword>
  <keyword>liver metastases</keyword>
  <keyword>lung metastases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Calcium</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

